Matthew Bennett
Vascular Surgery · Seattle, WANPI 1043579600
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $14,515 of the $22,902 with a category attached, or 63.4%. Genentech USA, Inc. accounts for 86.6% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2019 at $20,664 and has fallen 93.1% since, to $1,417 in 2025.
Across 92 payments — averaging $248.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$20K
- W. L. Gore & Associates, Inc.$2K
- Cook Medical LLC$566
- Medtronic$218
- Shockwave Medical, Inc$216
- Silk Road Medical, Inc.$159
- plus $257 from 6 others
What the payments were for
- Speaking & faculty fees$5,52524%
- Travel & lodging$14,51563%
- Food & beverage$2,86112%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 58 | $19,841 |
| W. L. Gore & Associates, Inc. | 12 | $1,645 |
| Cook Medical LLC | 7 | $566 |
| Medtronic | 4 | $218 |
| Shockwave Medical, Inc | 3 | $216 |
| Silk Road Medical, Inc. | 1 | $159 |
| KCI USA, Inc. | 1 | $118 |
| Biom'up France SAS | 2 | $74 |
| Johnson & Johnson | 1 | $27 |
| Inari Medical, Inc. | 1 | $20 |
| Venclose Inc. | 1 | $9 |
| Cardiovascular Systems Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- HEMLIBRA$18,600
- GORE TAG Thoracic Branch Endoprosthesis$1,022
- EXCLUDER AAA Endoprosthesis$248
- Zenith Spiral-Z$228
- Shockwave Intravascular Lithotripsy (IVL) System with the Shockwave E8 Peripher$173
- ENROUTE Transcarotid Neuroprotection System$159
- ENROUTE Transcarotid Stent System$159
- ENHANCE Transcarotid Peripheral Access Kit$159
- ENROUTE 0.014 Guidewire$159
- Valiant Captivia$138
- GORE EXCLUDER AAA Endoprosthesis$124
- PREVENA$118
How this compares
$22,902 in reported general payments places this provider in the 85th percentile of 111 vascular surgery providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 11 | $6,228 |
| Cilostazol | 12 | $222 |
Paid to pharmacies, not to this prescriber.
Other vascular surgery in Seattle
- Sara ZettervallSeattle$126K
- Paul HayesSeattle$83K
- Elina QuirogaSeattle$69K
- Mark MeissnerSeattle$43K
- Niten SinghSeattle$33K
- Matthew SweetSeattle$28K
- Saideep BoseSeattle$18K
- Jake HemingwaySeattle$15K
- Jose TraniSeattle$13K
- Nam TranSeattle$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.